FORMULATION DEVELOPMENT AND EVALUATION OF TEMOZOLOMIDE LOADED HYDROGENATED SOYA PHOSPHATIDYLCHOLINE LIPOSOMES FOR THE TREATMENT OF BRAIN CANCER

Objective: The objective of this study was to encapsulate temozolomide (TMZ) in the liposomal formulation for the treatment of glioblastoma. TMZis one of the most effective substances in vitro against cells derived from glioblastoma. However, it may not have a significant effect in vivo due topoor penetration in brain which may be attributed to the blood-brain-barrier. The main objective of this investigation is to develop a liposomal drugdelivery system which could improve the brain targeting, and solve the treatment-related problems.Methods: In this study, TMZ loaded liposomes were prepared by ethanol injection method. The characterization of formulated liposomes was carriedout by vesicle size, entrapment efficiency, surface morphology, and in vitro drug release study. The prepared liposomes were also evaluated for celluptake and cell cytotoxicity studies.Results: Particle size and entrapment efficiency were found to be 105.7±3.9 nm and 78.25±0.98%, respectively. 75% of the entrapped drug wasreleased in 24 hrs from the selected liposomal formulation. Cell uptake study reveals that hydrogenated soya phosphatidylcholine (HSPC) loaded TMZliposomes interact with the glioblastoma cells and kill the cancer cells effectively. Cytotoxicity assay confirms that drug loaded HSPC liposomes aremore efficient with respect to killing of glioblastoma cells as compared to plain drug.Conclusion: These results suggest that the TMZ loaded HSPC liposome may serve as a proficient targeted drug delivery system for the effectivemanagement of glioblastoma.Keywords: Temozolomide, Liposomes, Hydrogenated soya phosphatidylcholine, Cholesterol, Glioblastoma

FORMULATION AND EVALUATION OF CONTROLLED POROSITY OSMOTIC PUMP TABLETS OF GLIMEPIRIDE

A Controlled porosity of the membrane is accomplished by the use of pore former. The usual dose of glimepiride was 4 mg to be taken twice daily. The plasma half life of glimepiride was 5 h. Hence, glimepiride was chosen as a model drug with an aim to develop a controlled release system for 24 h. Sodium chloride was use as osmogent. Cellulose acetate was used as the semi permeable membrane. The porous osmotic pump contains pore forming water-soluble additive (Poly ethylene glycol 400) in the coating membrane which after coming in contact with water, dissolve, resulting in an in situ formation of microporous structure. The effect of different formulation variables, namely, ratio of drug to osmogent, membrane weight gain and concentration of pore former on the in vitro release was studied using 23 full factorial design. The effect of pH and agitation intensity on drug release was also studied. It was found that drug release rate increased with the amount of osmogent because of increased water uptake. Drug release was inversely proportional to membrane weight gain. Surface plot is also presented to graphically represent the effect of independent variables on t90. Optimized formulation was found to release above 90% of glimepiride at a zero order rate for 24 h

Heavy Flavour Baryons in Hyper Central Model

Heavy flavor baryons containing single and double charm (beauty) quarks with light flavor combinations are studied using the hyper central description of the three-body problem. The confinement potential is assumed as hyper central coulomb plus power potential with power index $\upsilon$. The ground state masses of the heavy flavor, $J^P={1/2}^+$ and ${3/2}^+$ baryons are computed for different power index, $\nu$ starting from 0.5 to 2.0. The predicted masses are found to attain a saturated value in each case of quark combinations beyond the power index $\nu=1.0$.Comment: 10 pages, 4 figure

Properties of Light Flavour Baryons in Hypercentral quark model

The light flavour baryons are studied within the quark model using the hyper central description of the three-body system. The confinement potential is assumed as hypercentral coulomb plus power potential ($hCPP_\nu$) with power index $\nu$. The masses and magnetic moments of light flavour baryons are computed for different power index, $\nu$ starting from 0.5 to 1.5. The predicted masses and magnetic moments are found to attain a saturated value with respect to variation in $\nu$ beyond the power index $\nu>$ 1.0. Further we computed transition magnetic moments and radiative decay width of light flavour baryons. The results are in good agreement with known experimental as well as other theoretical models.Comment: Accepted in Pramana J. of Physic

Properties of QQˉQ\bar{Q} (Qϵb,c)(Q \epsilon b, c) mesons in Coulomb plus Power potential

The decay rates and spectroscopy of the $Q \bar Q$ $(Q \in c, b)$ mesons are computed in non-relativistic phenomenological quark antiquark potential of the type $V(r)=-\frac{\alpha_c}{r}+A r^{\nu}$, (CPP$_{\nu}$) with different choices $\nu$. Numerical solution of the schrodinger equation has been used to obtain the spectroscopy of $Q\bar{Q}$ mesons. The spin hyperfine, spin-orbit and tensor components of the one gluon exchange interaction are employed to compute the spectroscopy of the few lower $S$ and orbital excited states. The numerically obtained radial solutions are employed to obtain the decay constant, di-gamma and di-leptonic decay widths. The decay widths are determined with and without radiative corrections. Present results are compared with other potential model predictions as well as with the known experimental values.Comment: 22 Pages, 1 Figur

Experience of first few cases of hiatus hernia surgery, without modern energy devices, at our institution

Background and objective: Gastro-esophageal reflux disease (GERD) with or without hiatus hernia is the most common benign medical condition of the stomach and esophagus. Our objective was to see results of surgery, when performed in low volume centre, by a general surgeon. Methodology: Our first 8 patients with GERD (with or without hiatus hernia) were operated by Nissen’s fundoplication. Prospectively we are describing our experience. Results: As a general surgeon laparoscopic Nissen’s fundoplication proved difficult and each time we had to resort to open surgery. No major complication reported till date. Conclusion: Although laparoscopic Nissen’s fundoplication has a steep learning curve, open surgery is much easier, faster and results are highly satisfactory. A General surgeon having enough knowledge of G-E junction anatomy should not afraid of doing open fundoplication

Robotic repair of a rare case of symptomatic "Ureterosciatic Hernia"

Ureterosciatic hernia (USH) is a rarely described entity and is an extremely rare cause of refractory flank pain. We report the diagnostic dilemma, and sequential endourological and finally the successful robotic management of one such symptomatic USH in an elderly woman who had presented with ipsilateral refractory flank pain, hydroureteronephrosis, and compromised renal function. We have also reviewed the current literature regarding the etiopathogenesis, presentation, diagnosis, and management of USHs. To the best of our knowledge, this is the first such case to describe the robotic-assisted laparoscopic management of a case of USH

Delayed inflammation associated with retained perfluorocarbon liquid

A 55-year-old woman, with history of cataract surgery 1 year back, presented with features of ocular inflammation for last 3 months. She had no history of any other intraocular surgery. On examination, anterior segment showed frothy material in the inferior angle with moderate anterior chamber reaction (cells+/flare+) and sulcus intraocular lens with large posterior capsule rent. Fundoscopy showed multiple, small to medium-sized transparent bubbles of perfluorocarbon liquid (PFCL) with membranes in the vitreous cavity. Ultrasonography confirmed the presence of PFCL in the vitreous cavity. Pars plana vitrectomy with anterior chamber wash was done which led to good visual recovery. To conclude, retained PFCL can cause late onset fibrinous inflammation after a quiescent period but surgical intervention may lead to good visual outcome

Robot-assisted laparoscopic radical prostatectomy after heart transplantation

Prostate cancer (CaP) is the leading visceral malignancy in males. Patients who undergo cardiac transplantation are immune compromised, thus presenting a therapeutic challenge. Immunosuppresion could accelerate tumor growth, while medical intervention may be associated with increased treatment mortality or morbidity. Due to paucity of such cases, there are no randomized trials that address the treatment algorithm for cardiac transplant patients with CaP, with only a few scattered reports in the literature. Treatment options range from hormonal manipulation to radiation therapy to radical prostatectomy. To our knowledge, we report the first successful robot-assisted laparoscopic radical prostatectomy in a heart transplant patient with CaP